EC
EcoR1 Capital Portfolio holdings
AUM
$1.69B
This Quarter Return
-11.3%
1 Year Return
+7.54%
3 Year Return
+113.08%
5 Year Return
+306.58%
10 Year Return
+4,328.75%
AUM
$957M
AUM Growth
+$957M
(-9.2%)
Cap. Flow
+$74.6M
Cap. Flow
% of AUM
7.79%
Top 10 Holdings %
Top 10 Hldgs %
58.48%
Holding
64
New
21
Increased
9
Reduced
14
Closed
12
Top Buys
| 1 |
Fate Therapeutics
FATE
|
$42M |
| 2 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$22.5M |
| 3 |
Puma Biotechnology
PBYI
|
$21.4M |
| 4 |
AnaptysBio
ANAB
|
$15.1M |
| 5 |
Sangamo Therapeutics
SGMO
|
$14.7M |
Top Sells
| 1 |
argenx
ARGX
|
$32.4M |
| 2 |
FibroGen
FGEN
|
$21.2M |
| 3 |
HARP
Harpoon Therapeutics, Inc. Common Stock
HARP
|
$13.4M |
| 4 |
SAGE
Sage Therapeutics
SAGE
|
$12.5M |
| 5 |
Acadia Pharmaceuticals
ACAD
|
$7.44M |
Sector Composition
| 1 | Healthcare | 92.25% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Prothena Corp
PRTA
$441M
| $101M | 10.54% | 9,426,640 | – | – |
|
2
Xencor
XNCR
$580M
| $74.7M | 7.81% | 2,501,557 | – | – |
|
3
Arvinas
ARVN
$568M
| $61.6M | 6.43% | 1,528,031 +188,962 | +14% | +$7.62M |
|
|
DRNA
4
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $61.5M | 6.42% | 3,346,301 -281,296 | -8% | -$5.17M |
|
|
5
Fate Therapeutics
FATE
$120M
| $52M | 5.43% | 2,341,875 +1,890,521 | +419% | +$42M |
|
6
Ironwood Pharmaceuticals
IRWD
$214M
| $44.3M | 4.63% | 4,393,236 +21,828 | +0.5% | +$220K |
|
|
7
AnaptysBio
ANAB
$569M
| $42.9M | 4.48% | 3,036,014 +1,069,914 | +54% | +$15.1M |
|
8
Neurogene
NGNE
$264M
| $42M | 4.39% | 3,693,203 -222,677 | -6% | -$2.53M |
|
|
MORF
9
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $41.4M | 4.33% | 2,823,141 +668,296 | +31% | +$9.81M |
|
10
Assembly Biosciences
ASMB
$190M
| $38.4M | 4.01% | 2,590,680 +202,412 | +8% | +$3M |
|
11
Kura Oncology
KURA
$686M
| $34.9M | 3.65% | 3,511,690 -730,263 | -17% | -$7.27M |
|
|
12
FibroGen
FGEN
$47.8M
| $30.7M | 3.2% | 882,138 -610,083 | -41% | -$21.2M |
|
|
IPHA
13
Innate Pharma
IPHA
$199M
| $29.8M | 3.12% | 4,465,668 -79,786 | -2% | -$533K |
|
|
MRTX
14
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $27.5M | 2.87% | 357,849 +292,849 | +451% | +$22.5M |
|
|
PRVL
15
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
| $27.4M | 2.86% | 2,248,306 | – | – |
|
|
16
Puma Biotechnology
PBYI
$254M
| $21.4M | 2.24% | +2,536,156 | New | +$21.4M |
|
17
Merus
MRUS
$4.98B
| $20.8M | 2.17% | 1,715,962 -2,238 | -0.1% | -$27.1K |
|
|
BCEL
18
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
| $18.3M | 1.91% | 1,106,180 -375,231 | -25% | -$6.21M |
|
19
Ultragenyx Pharmaceutical
RARE
$2.89B
| $16.5M | 1.72% | 371,208 +109,654 | +42% | +$4.87M |
|
|
20
Sangamo Therapeutics
SGMO
$157M
| $14.7M | 1.54% | +2,308,079 | New | +$14.7M |
|
21
Genmab
GMAB
$15.3B
| $13.9M | 1.45% | +653,981 | New | +$13.9M |
|
|
22
Acadia Pharmaceuticals
ACAD
$4.38B
| $13.7M | 1.43% | 323,889 -176,111 | -35% | -$7.44M |
|
23
Denali Therapeutics
DNLI
$2.23B
| $12.2M | 1.28% | +698,101 | New | +$12.2M |
|
24
Amicus Therapeutics
FOLD
$2.34B
| $11.5M | 1.21% | +1,249,611 | New | +$11.5M |
|
25
Cartesian Therapeutics
RNAC
$261M
| $11.1M | 1.16% | 4,597,701 | – | – |
|